The rapid uptake of ZELSUVMI, combined with low incremental SG&A for new product launches and strong balance sheet support, suggests accelerating revenue growth in 2026. Traders should monitor upcoming quarterly revenue trends and gross-to-net metrics to confirm margin sustainability.
Price Chart
Executive Summary
Pelthos Therapeutics reported strong Q4 and full-year 2025 financial results, driven by 28% quarter-over-quarter growth in ZELSUVMI net product revenue to $9.1 million, with total 2025 revenue reaching $16.8 million. The company also expanded its dermatology portfolio through the acquisitions of XEPI and XEGLYZE, secured $48 million in financing, and grew its sales force to 64 representatives. Despite a net loss, operating loss and Adjusted EBITDA both improved significantly in Q4.
Key Financial Metrics
Key Facts
- ZELSUVMI net product revenue grew 28% QoQ to $9.1 million in Q4 2025, up from $7.1 million in Q3.
- Total revenue for 2025 was $16.8 million, including $16.2 million from ZELSUVMI and $589,000 from licensing.
- Units dispensed surged 129% QoQ from 2,716 in Q3 to 6,232 in Q4 2025.
- Operating loss improved from $15.4 million in Q3 to $12.0 million in Q4 2025.
- Adjusted EBITDA improved from a loss of $11.5 million in Q3 to $9.0 million in Q4 2025.
- Company completed $18.0 million convertible note financing in November 2025 and drew $30.0 million from a $50.0 million term loan in January 2026.
- Acquired XEPI in November 2025 and XEGLYZE in January 2026, expanding pediatric dermatology portfolio.
- Cash balance was $18.0 million as of December 31, 2025; sales force expanded to 64 reps.
Financial Impact
Q4 revenue of $9.4 million, full-year revenue of $16.8 million, with ZELSUVMI showing strong commercial traction and cost efficiencies. Adjusted COGS dropped to $118K in Q4, indicating improved gross margins.
Risk Factors
- Net loss widened year-over-year due to change in fair value of convertible debt ($15.0 million non-cash charge).
- Heavy reliance on non-GAAP metrics like Adjusted EBITDA may obscure underlying cash burn.
- Future profitability depends on successful integration and commercialization of XEPI and XEGLYZE.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258816 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | 8-K | $20.60 $20.50 | ▼ −0.49% | ▼ −1.65% | $17.01 (−17.43%) |
Aug 13, 2026 10w ago | 8-K | $28.95 $26.66 | ▲ +7.91% | ▲ +5.95% | $17.01 (+41.24%) |
Aug 3, 2026 12w ago | Press Release | $26.84 | awaiting T+5 | — | $17.01 (−36.62%) |
Jun 17, 2026 18w ago | Insider Cluster | $29.00 $29.21 | ▲ +0.72% | ▲ +2.39% | $17.01 (−41.34%) |
May 28, 2026 21w ago | 8-K | $26.47 $25.55 | ▼ −3.48% | ▼ −0.95% | $17.01 (−35.74%) |
May 22, 2026 22w ago | 144 | $26.66 $26.20 | ▼ −1.73% | ▼ −3.40% | $17.01 (−36.20%) |
May 21, 2026 22w ago | 8-K | $26.66 $26.20 | ▲ +1.73% | ▲ +3.38% | $17.01 (+36.20%) |
May 14, 2026 23w ago | 8-K | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
May 14, 2026 23w ago | Press Release | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
Apr 20, 2026 26w ago | 3 | $23.00 $24.97 | ▲ +8.57% | ▲ +7.48% | $17.01 (−26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers